Bausch Health Companies Inc.
BHCNYSE
$4.83
↓ -2.0%Jul 17 close · end-of-day
Price
1Y↓ -25.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.8B
Enterprise Value
$21.3B
P/E
—
P/S
0.2
P/B
—
EV/EBITDA
11.9
PEG
—
FCF Yield
57.1%
Dividend Yield
—
Revenue (TTM)
$10.5B
Net Income (TTM)
-$1.2B
Free Cash Flow (TTM)
$1.0B
Gross Margin
—
Operating Margin
5.6%
Net Margin
-11.5%
ROE
58.7%
ROIC
2.7%
Debt / Equity
-10.1
Net Cash
-$19.5B
Return 1Y
-25.5%
Company profile
Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products. The Salix segment provides gastroenterology products in the United States. The Ortho Dermatologics segment provides dermatological products in United States; and Solta medical aesthetic devices internationally.
- CEO
- Thomas J. Appio
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 19,900
- Headquarters
- Quebec
- Website
- bauschhealth.com
Management & directors
- Lenar Aimee J.President, US Pharma
- Lee Steven HyosigSVP, Controller & CAO
- Carson SeanaEVP, General Counsel
- Appio ThomasChief Executive Officer
- Charhon Jean-JacquesEVP, CFO
Roles derived from SEC Form 4 filings.
Earnings
BHC Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$2.5B↑ +11.7%
Diluted EPS-$3.82↑ +2287.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $8.0B | $8.4B | $8.1B | $8.8B | $9.6B | $10.3B |
| Gross profit | — | — | — | — | — | — |
| Operating income | $676.0M | $450.0M | $454.0M | $963.0M | $1.5B | $1.8B |
| Net income | -$560.0M | -$948.0M | -$225.0M | -$592.0M | -$46.0M | $157.0M |
| Diluted EPS | -$1.58 | -$2.64 | -$0.62 | -$1.62 | -$0.13 | $0.42 |
| Operating cash flow | $1.1B | $1.4B | -$728.0M | $1.0B | $1.6B | $1.4B |
| Free cash flow | $809.0M | $1.2B | -$946.0M | $817.0M | $1.3B | $1.0B |
| Gross margin | — | — | — | — | — | — |
| Operating margin | 8.4% | 5.3% | 5.6% | 11.0% | 16.1% | 17.7% |
| Net margin | -7.0% | -11.2% | -2.8% | -6.8% | -0.5% | 1.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.4B | $2.5B | $2.6B | $2.3B | $2.5B | $2.7B | $2.8B | $2.5B |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $389.0M | $318.0M | $558.0M | $276.0M | $444.0M | $619.0M | $474.0M | -$950.0M |
| Net income | $10.0M | -$85.0M | $93.0M | -$58.0M | $148.0M | $179.0M | -$112.0M | -$1.4B |
| Diluted EPS | $0.03 | -$0.23 | $0.24 | -$0.16 | $0.40 | $0.48 | -$0.30 | -$3.82 |
| Operating cash flow | $380.0M | $405.0M | $601.0M | $211.0M | $289.0M | $405.0M | $495.0M | $230.0M |
| Free cash flow | $302.0M | $334.0M | $495.0M | $96.0M | $190.0M | $314.0M | $403.0M | $121.0M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 16.2% | 12.7% | 21.8% | 12.2% | 17.5% | 23.1% | 17.0% | -37.6% |
| Net margin | 0.4% | -3.4% | 3.6% | -2.6% | 5.8% | 6.7% | -4.0% | -56.4% |
Company news
Jul 12, 2026
Jul 7, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-15 | Lenar Aimee J.· President, US Pharma | Tax withholding | 23,395 | $4.89 | $114,401.55 | filing |
| 2026-07-14 | LEE STEVEN HYOSIG· SVP, Controller & CAO | Tax withholding | 3,125 | $4.75 | $14,843.75 | filing |
| 2026-06-30 | Paulson John | Award | 12,677 | $4.93 | $62,497.61 | filing |
| 2026-06-30 | LEUNG SANDRA | Award | 6,845 | $4.93 | $33,745.85 | filing |
| 2026-06-30 | WECHSLER AMY B | Award | 1,394 | $4.93 | $6,872.42 | filing |
| 2026-05-22 | LEUNG SANDRA | Award | 45,871 | $0.00 | $0.00 | filing |
| 2026-05-22 | Lee Frank D. | Award | 45,871 | $0.00 | $0.00 | filing |
| 2026-05-22 | KAVANAGH SARAH B | Award | 45,871 | $0.00 | $0.00 | filing |
| 2026-05-22 | GOETTLER MICHAEL | Award | 45,871 | $0.00 | $0.00 | filing |
| 2026-05-22 | Garcia Christian A | Award | 45,871 | $0.00 | $0.00 | filing |
| 2026-05-22 | WECHSLER AMY B | Award | 45,871 | $0.00 | $0.00 | filing |
| 2026-05-22 | ROBERTS EIRY | Award | 45,871 | $0.00 | $0.00 | filing |
| 2026-05-22 | POWER ROBERT N | Award | 45,871 | $0.00 | $0.00 | filing |
| 2026-05-22 | Paulson John | Award | 45,871 | $0.00 | $0.00 | filing |
| 2026-05-19 | Lee Frank D. | Sale | 24,456 | $5.43 | $132,796.08 | filing |
| 2026-03-31 | Paulson John | Award | 11,574 | $5.40 | $62,499.60 | filing |
| 2026-03-31 | LEUNG SANDRA | Award | 5,946 | $5.40 | $32,108.40 | filing |
| 2026-03-31 | WECHSLER AMY B | Award | 1,273 | $5.40 | $6,874.20 | filing |
| 2026-03-03 | Carson Seana· EVP, General Counsel | Sale | 4,420 | $5.77 | $25,503.40 | filing |
| 2026-03-02 | APPIO THOMAS· Chief Executive Officer | J | 1,137,862 | $5.95 | $6.8M | filing |
| 2026-03-02 | Carson Seana· EVP, General Counsel | J | 137,922 | $5.95 | $820,635.90 | filing |
| 2026-03-02 | APPIO THOMAS· Chief Executive Officer | Tax withholding | 83,705 | $5.95 | $498,044.75 | filing |
| 2026-03-02 | Carson Seana· EVP, General Counsel | Tax withholding | 16,973 | $5.95 | $100,989.35 | filing |
| 2026-03-02 | Carson Seana· EVP, General Counsel | Sale | 6,856 | $5.78 | $39,627.68 | filing |
| 2026-02-27 | APPIO THOMAS· Chief Executive Officer | Tax withholding | 83,093 | $5.93 | $492,741.49 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.